38 results about "Late gastric cancer" patented technology

The present invention relates to a humanized antibody binding to claudin 18.2 for treating cancer. The antibody does not bind to Claudin 18.1, but selectively binds to Claudin 18.2 to destroy tight connection between cells, so that the Claudin 18.2 cannot exert normal functions, and the antibody can be used for preventing or treating tumors, especially advanced gastric cancer.

The invention relates to an anti-Claudin18.2 fully-humanized monoclonal antibody for treatment of late gastric cancer. The antibody has higher humanization degree and relatively lower immunogenicity compared with the existing Claudin18.2 antibody IMAB362 of Ganymed, selectively binds to CLDN18.2, and has relatively higher affinity.

The invention provides interfering RNA and a lentivirus vector targeted to the OLFM4 gene and application of the interfering RNA and the lentivirus vector in preparation of drugs used for preventing and treating metastasis of stomach cancer tumors to the abdominal cavity or/and the liver. According to the invention, since the interfering RNA can inhibit in vitro migration and invasion ability of gastric cancer cells and liver metastasis capability of gastric cancer cells, decreased expression of OLFM4 is a potential effective mode for treatment of malignant progression of late gastric cancer. It is further determined that an NF-kB signal is an upstream regulation transcription factor of expression of OLFM4 and the interfering RNA has NF-kB signal feeding back and regulating functions.

The invention discloses a late gastric cancer survival prediction method based on integrated learning, and the method comprises the steps: obtaining case data, and carrying out the data screening, and obtaining a data set; constructing a prediction model and training the prediction model based on the data set to obtain a completely trained prediction model; and evaluating the training complete prediction model based on the confusion matrix and the working curve. Aiming at the characteristic of imbalance of survival samples of advanced gastric cancer, the clinical prognosis model established by adopting an integrated learning technology can solve the problem of overfitting. The advanced gastric cancer survival prediction method based on ensemble learning can be widely applied to the field of medical data processing.

The invention provides a formula and preparation method of Hui-nationality traditional Chinese medicine aralia root bark granules for treating gastric cancer. The medicine is a green and high-tech traditional Chinese medicine for treating advanced gastric cancer, especially the advanced gastric cancer which cannot be subjected to a surgery due to various reasons. The Hui-nationality traditional Chinese medicine aralia root bark granules are traditional Chinese medicine granules prepared by mixing traditional Chinese medicines including aralia root bark, rhizoma curcumae, herba sarcandrae, fiveleaf akebia fruit, seaweed, cortex ailanthi, aloe and the like at a certain ratio, adding water and decocting, extracting, concentrating and granulating. The Hui-nationality traditional Chinese medicine aralia root bark granules are used for mainly treating the gastric cancer and can also be used for treating digestive system cancers including pharyngolaryngeal cancer, esophageal cancer, cardiac cancer, colorectal cancer and the like. The Hui-nationality traditional Chinese medicine aralia root bark granules have the characteristics of a few of medicines and moderate dosage; modern medicine pharmacological experiments of most of the selected medicines show that the medicines can be used for treating the cancer.

The invention discloses an immunofluorescence kit for detecting PD-L1 expression of peripheral blood circulating tumor cells of a gastric cancer patient and a detection method. Circulating tumor cells(CTCs) in peripheral blood of an advanced gastric cancer patient are separated by using a membrane filtration device, and the PD-L1 expression condition on the CTCs is further detected by using an immunofluorescence technology. According to the detection method provided by the invention, the PD-L1 expression condition of a patient suffering from advanced or recurrent gastric cancer can be detected without obtaining a tissue specimen through needle biopsy. According to the method provided by the invention, the circulating tumor cells are well separated, the interference of blood cells can be avoided, a false positive result caused by an edge effect possibly generated in a dyeing process can be avoided, the stability is good, the loss of the cells is reduced, and the detection accuracy is improved. The marker PD-L1 shows good specificity and sensitivity in use, and the application of the marker PD-L1 in gastric cancer is improved.

The invention discloses an immunofluorescence kit and a detection method for detecting expression of peripheral blood circulating tumor cells CA125 of a gastric cancer patient. Circulating tumor cells(CTC) in peripheral blood of the patient suffering from advanced gastric cancer are obtained through separation by using a membrane filtration device, and the expression condition of CA125 on CTC isfurther detected by using an immunofluorescence technology. According to the detection method provided by the invention, the CA125 expression condition of the patient suffering from advanced or recurrent gastric cancer can be detected without obtaining a tissue specimen through needle biopsy. According to the method provided by the invention, the circulating tumor cells are well separated, interference of blood cells can be avoided, a false positive result caused by an edge effect possibly generated in a dyeing process can be avoided, the stability is high, the loss of the cells is reduced, and the detection accuracy is improved. The marker CA125 shows high specificity and sensitivity in use, and application of the marker CA125 in gastric cancer is enhanced.

The invention discloses a HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on VEGFA and application thereof, the model comprises a line chart used for evaluating chemotherapy curative effect, scores corresponding to four indexes BMI, Diagnose Pattern, VEGFA and CA19-9 in the first row from the second row to the fifth row are added to obtain a total score of a sixth row of patients, and the total score of the sixth row of patients is calculated to obtain the first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect. And correspondingly projecting the total score of the patient in the sixth row to the seventh row to obtain the probability that the treatment of the patient is invalid. The curative effect prediction line diagram integrating serum VEGFA and common baseline characteristics is simple, clear, popular and easy to understand, and clinical doctors and patients can conveniently perform operation to predict the curative effect. Meanwhile, a satisfactory prediction result is displayed by a curative effect line diagram, clinical judgment and layering can be better guided, and certain help is provided for treatment of HER2 negative advanced gastric cancer patients in the future.

The invention specifically relates to nutritious food for people with gastric cancer and a preparation method thereof, belonging to the technical field of nutritious food. The nutritious food for people with gastric cancer contains nutritive elements consisting of protein, fat, carbohydrates, vitamins, mineral substances, amino acids, EPA, ginkgo flavonoids and nucleotide. Besides providing sufficient and comprehensive nutrients for the body, the nutritious food of the invention further enhances the barrier function of the gastric mucosa, better accords with metabolic physiological states, facilitates the protein synthesis and metabolic regulation of the body, promotes the recovery of gastric functions and morphology, prevents the translocation of bacteria and toxins and significantly reduces the incidence of stomach-derived infections; and the nutritious food is an effective means for improving the nutritional status of patients receiving chemotherapy. The nutritious food can improvethe nutritional status of chemotherapy patients with advanced gastric cancer, reduce the adverse reactions of the patients, and effectively improve the immunity of the patients.

The invention discloses a traditional Chinese medicine formula for treating stomach cancer with syndrome of deficiency of spleen and stomach and accumulation of blood stasis toxin. The traditional Chinese medicine formula comprises the following raw materials of, in parts by weight, 5 parts-15 parts of radix pseudostellariae, 20 parts-40 parts of astragalus membranaceus, 10 parts-20 parts of parched rhizoma atractylodis macrocephalae, 20 parts-40 parts of coix seeds, 10 parts-20 parts of hairyvein agrimony, 20 parts-40 parts of oldenlandia diffusa, 10 parts-20 parts of sculellaria barbata, 5 parts-15 parts of liquorice, 2 parts-10 parts of nidus vespae, 10 parts-20 parts of fingered citron, 5 parts-15 parts of elecampane, 8 parts-16 parts of curcuma zedoary, 10 parts-30 parts of salvia miltiorrhiza, 20 parts-40 parts of kelp and 10 parts-30 parts of parched white peony root. The traditional Chinese medicine formula is exact in clinical effect, and the effective rate on stomach cancer (middle-late stage) caused by deficiency of spleen and stomach and stagnation of blood stasis toxin is 97% or above; the life of a patient with conservative treatment on stomach cancer can be prolonged; the rehabilitation treatment effect is still achieved after the stomach cancer operation; the traditional Chinese medicine formula is widely applied to clinical conservative treatment of middle and late stomach cancer, and can also be used for adjuvant therapy of stomach cancer chemotherapy and prevention; and the traditional Chinese medicine formula can be prepared into powder, pills or capsules for administration, and is very convenient for clinical use.

According to the invention, CLDN18.2 positive CTC detected in peripheral blood of a patient suffering from advanced gastric cancer or CLDN18.2 positive DTC detected in ascites of a patient suffering from peritoneal metastasis gastric cancer is disclosed for the first time, so that the patient is indicated to have shorter PFS and OS, the treatment effect and total survival of the patient suffering from advanced gastric cancer can be effectively predicted before treatment, only 6 mL of peripheral blood sample of the patient suffering from gastric cancer needs to be extracted during operation, and the operation is simple and convenient. Complex surgery and pathological material taking under an endoscope are not needed, the specimen obtaining process is more minimally invasive and safer, and the method has extremely high popularization value.

The invention relates to a formula and a preparation method of a Hui nationality traditional Chinese medicinal ginseng and Araiia chinensis L. root bark stomach cancer treatment tablet. The tablet is a green high-tech Chinese herbal medicine used for treating late stomach cancer, especially late stomach cancer which cannot be operated due to various reasons. The tablet is a traditional Chinese medicinal tablet prepared through the following steps: mixing of Araiia chinensis L. root bark, Rhizoma Curcumae, glabrous sarcandra herb, fiveleaf akebia fruit, seaweeds, Cortex Ailanthi, aloe and other Chinese herbal medicines in proportion, water adding, decoction, extraction, concentration and tabletting. The tablet is mainly used for treating the stomach cancer, and also is used for treating the throat cancer, the esophagus cancer, the cardiac cancer, the colorectal cancer and other digestive system cancers. The tablet has the characteristics of small medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers.

The invention discloses a pharmaceutical composition with an anticancer effect. The pharmaceutical composition consists of the following components: 6-25 parts of Blaps rynchopetera Fairmaire, 4-15 parts of ants, 5-10 parts of Sculellaria barbata, 10-20 parts of Indian strawberry, 15-25 parts of Astragalus, 5-17 parts of Codonopsis pilosula, 10-45 parts of Angelica sinensis, 5-12 parts of honeysuckle and 5-13 parts of Radix Adenophorae. The anticancer pharmaceutical composition disclosed by the invention has an obvious effect of treating cancers and particularly has unexpected excellent curative effects on terminal cancers which are unsuitable for operations and chemoradiotherapy or are ineffective to operations and chemoradiotherapy. According to clinical follow-up statistics of 90 cases suffering from various terminal cancers for over ten years, the anticancer pharmaceutical composition disclosed by the invention has the advantages that the total effective rate is about 90 percent, the total cure rate is about 30 percent, the survival rate within three years is about 40 percent, and the survival rate within five years is about 25 percent. Moreover, the anticancer pharmaceutical composition disclosed by the invention is particularly outstanding in curative effect on late gastric cancer, the effective rate is 100 percent, the cure rate is about 80 percent, the survival rate within three years is about 90 percent, and the survival rate within five years is about 80 percent.

The invention provides Hui nationality traditional Chinese medicine curcuma zedoaria stomach cancer-dispersing tablets and a preparation method thereof. The tablets are Chinese herbal medicine with environmental friendlessness as well as high science and technology for treating stomach cancer, especially stomach cancer with difficult operation at a late period due to various reasons; the Hui nationality traditional Chinese medicine curcuma zedoaria stomach cancer-dispersing tablets comprise the raw materials of curcuma zedoaria, salvia chinensis, rhizoma polygonati, semen cuscutae, cortex acanthopanacis, tuber of dwarf lilyturf and camptotheca acuminata according to a certain proportion, and the preparation method comprises the steps of mixing, adding water, decocting, extracting, concentrating, and tabletting; and the curcuma zedoaria stomach cancer-dispersing tablets are used for mainly treating digestive system cancers such as stomach cancer, throat cancer, esophagus cancer, cardia cancer, and colorectal cancer. The curcuma zedoaria stomach cancer-dispersing tablets have the characteristics of moderate flavor and dosage, and the selected raw materials can be used for treating cancer through modern medical pharmacology experiments.

The invention specifically discloses a formula of a Hui-nationality traditional Chinese medicine oral solution with curcuma zedoary and semen cuscutae for treating gastric cancer and a preparation method thereof. The medicine is a green and high-tech traditional Chinese herbal medicine for treating late gastric cancer, especially the late gastric cancer which cannot be operated on because of various reasons. The medicine is a traditional Chinese medicine oral solution prepared by mixing traditional Chinese herbal medicines such as curcuma zedoary, herba salviae chinensis, rhizoma polygonati, semen cuscutae, cortex acanthopanacis, radix ophiopogonis and Fructus seu Radix Camptothecae Acuminatae and the like according to a certain ratio, adding water for decocting, extracting and concentrating. The traditional Chinese medicine oral solution is mainly used for treating gastric cancer and is also used for treating digestive system cancers such as pharyngolaryngeal cancer, esophagus cancer, cardiac cancer and colorectal cancer and the like. The traditional Chinese medicine oral solution has the characteristics of small amount of medicine and moderate dosage; the modern medical pharmacology experiments show that most of the selected traditional Chinese medicines can be used for treating cancers.

The invention provides a formula and preparation method of Hui-nationality traditional Chinese medicine taxus chinensis bark pills for treating gastric cancer. The medicine is a green and high-tech traditional Chinese medicine for treating advanced gastric cancer, especially the advanced gastric cancer which cannot be subjected to a surgery due to various reasons. The Hui-nationality traditional Chinese medicine taxus chinensis bark pills are traditional Chinese medicine pills prepared by mixing traditional Chinese medicines including taxus chinensis bark, rhizoma curcumae, radix actinidiae chinensis, herba andrographitis, cortex ailanthi, coix seed and the like at a certain ratio, adding water and decocting, extracting, concentrating and pilling. The Hui-nationality traditional Chinese medicine taxus chinensis bark pills are used for mainly treating the gastric cancer and can also be used for treating digestive system cancers including pharyngolaryngeal cancer, esophageal cancer, cardiac cancer, colorectal cancer and the like. The Hui-nationality traditional Chinese medicine taxus chinensis bark pills have the characteristics of a few of medicines and moderate dosage; modern medicine pharmacological experiments of most of the selected medicines show that the medicines can be used for treating the cancer.

The invention discloses a formula of a Hui nationality traditional Chinese medicine radix ginseng rubra gastric cancer killing pill and a preparation method thereof. The pill belongs to a green high-tech Chinese herbal medicine for treating a late gastric cancer, particularly a late gastric cancer which is not treated because an operation cannot be performed due to various reasons. The pill belongs to a traditional Chinese medicine pill formed by mixing Chinese herbal medicines, such as ficus carica, bittersweet herb, herba lobeliae chinensis, radix actinidiae chinensis, radix curcumae longae and akebia trifoliata koidz according to a certain ratio, boiling with water, extracting, concentrating and pelleting, mainly treats a gastric cancer, also treats digestive system cancers, such as a pharyngolaryngeal cancer, an esophagus cancer, a carcinoma of gastric cardia and a colorectal cancer, and has the characteristics that drugs are tasteless, the dosage is moderate, and most of selected drugs are proved, through modern medical pharmacological experiments, to be capable of treating cancers.

The invention specifically discloses a formula of a Hui-nationality traditional Chinese medicine tablet with ark shell, semen cuscutae and airpotato yam rhizome for treating gastric cancer and a preparation method thereof. The medicine is a green and high-tech traditional Chinese herbal medicine for treating late gastric cancer, especially the late gastric cancer which can not be treated by operation because of various reasons. The medicine is a traditional Chinese medicine tablet prepared by mixing traditional Chinese herbal medicines such as ark shell, semen cuscutae, airpotato yam rhizome, radix salviae miltiorrhizae, bark of aralia chinensis and Semen Entadae Phaseoloidis and the like according to a certain ratio, adding water for decocting, extracting, concentrating and tabletting. The traditional Chinese medicine tablet is mainly used for treating gastric cancer and is also used for treating digestive system cancers such as pharyngolaryngeal cancer, esophagus cancer, cardiac cancer and colorectal cancer and the like. The traditional Chinese medicine tablet has the characteristics of small amount of medicine and moderate dosage; the modern medical pharmacology experiments show that most of the selected traditional Chinese medicines can be used for treating cancers.

The invention discloses a formula of a Hui nationality traditional Chinese medicine rhizoma cyperi and akebia trifoliata koidz gastric cancer eliminating tablet and a preparation method thereof. The tablet belongs to a green high-tech Chinese herbal medicine for treating a late gastric cancer, particularly a late gastric cancer which is not treated because an operation cannot be performed due to various reasons. The tablet belongs to a traditional Chinese medicine tablet formed by mixing Chinese herbal medicines, such as radix astragali, radix codonopsis, herba salviae chinensis, sargassum, rhizoma polygonati, rhizoma cyperi and herba pteridis multifidae according to a certain ratio, boiling with water, extracting, concentrating and tabletting, mainly treats a gastric cancer, also treats digestive system cancers, such as a pharyngolaryngeal cancer, an esophagus cancer, a carcinoma of gastric cardia and a colorectal cancer, and has the characteristics that drugs are tasteless, the dosage is moderate, and most of selected drugs are proved, through modern medical pharmacological experiments, to be capable of treating cancers.

The invention discloses a formula of a Hui nationality traditional Chinese medicine concha arcae, semen cuscutae and rhizoma dioscoreae bulbiferae gastric cancer elimination oral liquid and a preparation method thereof. The oral liquid belongs to a green high-tech Chinese herbal medicine for treating a late gastric cancer, particularly a late gastric cancer which is not treated because an operation cannot be performed due to various reasons. The oral liquid belongs to a traditional Chinese medicine oral liquid formed by mixing Chinese herbal medicines, such as concha arcae, semen cuscutae, rhizoma dioscoreae bulbiferae, radix salviae miltiorrhizae, radix et cortex araliae and entada phaseoloide according to a certain ratio, boiling with water, extracting and concentrating, mainly treats a gastric cancer, also treats digestive system cancers, such as a pharyngolaryngeal cancer, an esophagus cancer, a carcinoma of gastric cardia and a colorectal cancer, and has the characteristics that drugs are tasteless, the dosage is moderate, and most of selected drugs are proved, through modern medical pharmacological experiments, to be capable of treating cancers.

The present invention relates to a system for predicting prognosis and benefit from adjuvant chemotherapy for patients with stage II and III gastric cancer, and an algorithm that can predict prognosis and chemotherapy responsiveness using quantitative analysis results of mRNA expression levels of a prognosis or chemotherapy responsiveness-related marker gene group and a reference gene group in advanced gastric cancer is developed, and can be used as supplementary information to determine a method for treating a gastric cancer patient.